Edwards Lifesciences Corporation (NYSE:EW) came out with its third-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. It looks to have been a decent result overall - while revenue fell marginally short of analyst estimates at US$1.4b, statutory earnings beat expectations by a notable 855%, coming in at US$5.13 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Edwards Lifesciences after the latest results.

See our latest analysis for Edwards Lifesciences

Taking into account the latest results, the 29 analysts covering Edwards Lifesciences provided consensus estimates of US$5.93b revenue in 2025, which would reflect a small 6.1% decline over the past 12 months. Statutory earnings per share are expected to shrink 4.8% to US$2.48 in the same period. Before this earnings report, the analysts had been forecasting revenues of US$5.99b and earnings per share (EPS) of US$2.59 in 2025. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.

The consensus price target held steady at US$76.14, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Edwards Lifesciences analyst has a price target of US$96.80 per share, while the most pessimistic values it at US$63.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that revenue is expected to reverse, with a forecast 4.9% annualised decline to the end of 2025. That is a notable change from historical growth of 7.9% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 8.2% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Edwards Lifesciences is expected to lag the wider industry.